Key result
Ranolazine linked to improved symptoms and CMRI perfusion in a microvascular coronary dysfunction case.
Why the study?
Women with signs and symptoms of myocardial ischemia often have persistent symptoms and a high prevalence of microvascular coronary dysfunction without obstructive coronary artery disease.
Does ranolazine improve symptoms and myocardial perfusion in a patient with microvascular coronary dysfunction?
Case Report (n=1)
Does ranolazine improve symptoms and myocardial perfusion in a patient with microvascular coronary dysfunction?
Ranolazine may be an effective treatment for improving symptoms and myocardial perfusion in patients with microvascular coronary dysfunction and no obstructive coronary artery disease.
Answers are grounded in this paper and cite their sources.
MCD may explain persistent symptoms in young women with normal coronaries; this case leaves open optimal diagnostic and therapeutic strategies.
Women often exhibit persistent symptoms, functional disability and a relatively high prevalence of microvascular coronary dysfunction (MCD) with no obstructive coronary artery disease (CAD) when evaluated for signs and symptoms of myocardial ischemia. A 27-year-old woman was referred by her treating cardiologist for symptoms of persistent chest pain for 10 years. Cardiac catheterization showed normal coronary arteries. Given the constellation of persistent chest pain and no obstructive CAD, a diagnosis of MCD was suspected, and she underwent coronary reactivity testing (CRT) with intracoronary infusions of adenosine, acetylcholine and nitroglycerin to test nonendothelial- and endothelial-dependent, micro- and macro-vascular coronary function. CRT results were consistent with a diagnosis of MCD. The patient was started on ranolazine, with significant improvement in symptoms. Cardiac magnetic resonance imaging (CMRI) after 3 months of treatment demonstrated improvement in perfusion compared to baseline. J Med Cases. 2014;5(1):23-25 doi: http://dx.doi.org/10.4021/jmc1522w
No takes yet. Share an insight, caveat, or question.
Mian et al. (2014) conducted a case report in Microvascular coronary dysfunction (MCD) without obstructive coronary artery disease (n=1). Ranolazine was evaluated on Symptom improvement and myocardial perfusion on cardiac magnetic resonance imaging (CMRI). Ranolazine treatment for 3 months in a 27-year-old woman with microvascular coronary dysfunction led to significant symptom improvement and enhanced myocardial perfusion on CMRI.
Synapse has enriched 10 related papers. Consider them for comparative context: